In a new podcast, Anthony Feinstein discusses CogEx, a randomised trial of cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis.
Listen here: bit.ly/3EPYLNE
Read the study: hubs.li/Q02366rr0
2023 is a year of milestones at The Lancet Group. We mark the anniversary of six of our journals, including #Lancet200, amongst other notable achievements.
Hear from Richard Horton and the Editors-in-Chief of your favourite Lancet journals as they share their recent highlights, a look forward at what’s to come in their fields, and their curated collection of impactful papers published in recent years: hubs.li/Q022gMf30
Every year, journals around the world receive different metrics to reflect their performance. While only a limited measure of our impact, we are pleased to share that The Lancet ranks:
#1 in general and internal medicine with an Impact Factor of 168·9
#2 in general medicine with a Scopus CiteScore of 133·2
Congratulations to our authors and peer reviewers, whose expertise and hard work enable us to continue publishing the best science for better lives.
You can access our full reach and impact statement for more information here: hubs.li/Q01WmrBC0
Health is a fundamental human right. Yet every year, 8.6 million avoidable deaths occur due to low-quality or underused care in low- and middle-income countries. “Whether we call it Universal Health Coverage or National Health Service, I want people to
Health is a fundamental human right. Yet every year, 8.6 million avoidable deaths occur due to low-quality or underused care in low- and middle-income countries.
“Whether we call it Universal Health Coverage or National Health Service, I want people to feel that it is something owed to them by the government”, says Ṣẹ̀yẹ Abímbọ́lá, Associate Professor of Public Health at Sydney University.
As part of The Lancet's 200th anniversary, we are shining a spotlight on the importance of achieving universal health coverage en route to health for all.
Listen to experts from around the world as they share insights and discuss their own efforts to advance health 👇 #Lancet200
We are now in our 200th year! 🎉 In 1823, Thomas Wakley founded The Lancet on the belief that advancing research and science should drive change for the greater good—a belief we maintain today. Over the next 12 months, The Lancet Group has bold plans
We are now in our 200th year! 🎉
In 1823, Thomas Wakley founded The Lancet on the belief that advancing research and science should drive change for the greater good—a belief we maintain today.
Over the next 12 months, The Lancet Group has bold plans to celebrate, self-reflect, and amplify our impact and vision.
And we want you to join us.
Find out more 👉 https://hubs.li/Q01x9bgV0 #Lancet200
2022 has been another exceptional year for The Lancet Group.
Register today to receive a bespoke email from the Lancet journals of your choice, containing insights from our editors and curated collections of influential papers published in recent years 👉 hubs.li/Q01pXnCX0
A heart of iron: juvenile haemochromatosis presents with cardiac failure. Dr Iside Cartella walks us through the case of a 39 y/o man in this Clinical Picture ⤵️
A heart of iron: juvenile haemochromatosis presents with cardiac failure.
Dr Iside Cartella walks us through the case of a 39-year-old man in this Clinical Picture ⤵️
A 32-year-old right-handed woman presented to a neurology clinic with a 3-month history of intermittent blurriness of her vision and left-sided paraesthesia in her arm and leg. The patient said that the problems began shortly after she gave birth to her
A 32-year-old right-handed woman presented to a neurology clinic with a 3-month history of intermittent blurriness of her vision and left-sided paraesthesia in her arm and leg.
The patient said that the problems began shortly after she gave birth to her first child and gradually became worse over the following 12 weeks.
In this video, Devin V Bageac describes what led to a diagnosis of cerebellar hemangioblastoma 👇
The Lancet Commission on the Value of Death
"Death is not just a physiological event, an endpoint—it's so much more than that."
Dying in the 21st century is a story of paradox, with some overtreated in hospitals as family and community are pushed to the margins, and others left to face death alone.
This is especially true in low-income countries, where suffering is rendered near-invisible in relation to the high-income countries that prioritise life-extending interventions, irrespective of the quality of that life.
Watch as Commissioners of the Lancet Commission on the Value of Death, Libby Sallnow and M R Rajagopal, propose a 'realistic utopia' for death and dying, showing us why society's relationship with death must be rebalanced ⬇️ hubs.li/Q014FQVW0
A 57-year-old native English-speaking man had a 5-week history of becoming unable to understand words—despite hearing them. He also reported a constant noise sounding "like trucks". What's going on? Dr Jacob M Pogson explains 👇
A 57-year-old native English-speaking man had a 5-week history of becoming unable to understand words—despite hearing them.
He also reported a constant noise sounding "like trucks".
What's going on? Dr Jacob M Pogson explains 👇
An accurate, timely diagnosis can be the difference between life and death—yet 47% of the 🌍 population has little or no access to diagnostics. A new Lancet Commission on diagnostics outlines recommendations to accelerate and transform access worldwid
An accurate, timely diagnosis can be the difference between life and death—yet 47% of the 🌍 population has little or no access to diagnostics.
A new Lancet Commission on diagnostics outlines recommendations to accelerate and transform access worldwide: hubs.li/H0YZX6B0
📺 Watch a new Clinical Picture. In this video, immunotactoid glomerulopathy (ITG) associated with monoclonal gammopathy. ITG is a rare glomerular disease encountered in 0.06% of native kidney biopsies; its management remains poorly defined. It is chara
📺 Watch a new Clinical Picture. In this video, immunotactoid glomerulopathy (ITG) associated with monoclonal gammopathy. ITG is a rare glomerular disease encountered in 0.06% of native kidney biopsies; its management remains poorly defined. It is characterised by electron microscopic findings of deposits comprising straight, long microtubules with hollow cores and a diameter of greater than 30nm.
Watch to learn more and read https://hubs.li/H0Phx5s0 for the full case.
